A New Theory Explains Why One Natural Molecule May Influence Cancer on Multiple Fronts
For decades, scientists have known that melatonin does much more than regulate sleep. Research has repeatedly suggested that it can slow tumor growth, increase cancer cell death, reduce metastasis, improve immune responses, and even make conventional cancer treatments work better. Yet one major question has remained unanswered: How can one naturally occurring molecule influence so many different cancer pathways?
A newly published proof of concept analysis may offer the most comprehensive explanation yet. In a paper published June 17, 2026, researchers Doris Loh, Luiz Gustavo de Almeida Chuffa, Fábio Rodrigues Ferreira Seiva, and Russel J. Reiter propose that melatonin may act as a “master regulator” capable of disrupting many of cancer’s survival mechanisms simultaneously. Rather than targeting just one gene or one signaling pathway, the researchers argue that melatonin changes the physical environment that cancer cells depend upon to survive.
A Different Way of Looking at Cancer
The researchers focused on structures known as biomolecular condensates. These are tiny, membrane free compartments inside cells that organize important biological activities.
Under normal conditions, these condensates constantly form and dissolve as cells respond to changing conditions. Cancer cells, however, appear to hijack this process. Instead of remaining temporary, these condensates become stable “safe havens” that protect cancer promoting genes and allow malignant cells to continue growing, adapting, and resisting treatment.
According to the authors, these condensates become physical sanctuaries that help tumors survive even under intense stress.
Their central question became simple: Could melatonin interfere with these cancer sanctuaries?
An Extensive Scientific Investigation
Rather than conducting a single laboratory experiment, the investigators performed an enormous systematic review combined with sophisticated bioinformatics analysis.
They searched more than 14,000 scientific references using PubMed and Web of Science. After removing duplicates and screening the available literature, they narrowed the field to 207 studies that met their inclusion standards.
The team then integrated multiple scientific databases, including the Phase Separation Database, STRING protein interaction database, Gene Ontology analyses, transcription factor mapping, microRNA analysis, and survival information from The Cancer Genome Atlas.
By combining all of these resources, they searched for genes that were both involved in cancer related phase separation and known to respond to melatonin.
Twenty Six Critical Cancer Genes
The analysis identified 26 major genes sitting at the intersection of melatonin biology and cancer promoting condensates.
Many of these genes are already well known in oncology. They include MYC, TP53, EGFR, BCL2, YAP1, EZH2, CTNNB1, KEAP1, TWIST1, SOX9, VIM, and several others that regulate tumor growth, metastasis, therapy resistance, and cancer stem cells.
Perhaps most importantly, the researchers found that melatonin appears to reduce the activity of most of these cancer promoting genes while increasing activity of TP53, one of the body’s most important tumor suppressor genes.
This combination could shift the balance away from cancer survival and toward normal cellular control.
Three Ways Melatonin Fights Cancer
The researchers propose that melatonin attacks cancer through three interconnected biological mechanisms.
The first involves restoring normal redox balance.
Cancer cells maintain an abnormal chemical environment that protects their survival systems. According to the study, melatonin recalibrates this balance, stripping away many of the oxidative defenses that cancer cells depend upon while exposing them to conditions that favor their destruction.
The second mechanism involves disrupting the physical scaffolding that holds cancer’s molecular machinery together.
Many cancer proteins rely on numerous weak molecular interactions that collectively create stable condensates. The researchers suggest that melatonin acts like a “molecular plasticizer,” interfering with these interactions before the condensates can mature into stable structures.
Without these physical scaffolds, many cancer promoting proteins become far less effective.
The third mechanism changes the electrical properties inside cancer cells.
Tumors often create acidic microenvironments while protecting their internal machinery from these harsh conditions. The study proposes that melatonin alters the electrical and chemical properties inside condensates, effectively collapsing these protected environments and exposing cancer cells to conditions they can no longer tolerate.
Disrupting Cancer’s Survival Network
The researchers organized cancer’s protective condensates into three functional systems.
The first controls gene expression and determines which genes are turned on or off.
The second integrates signals that allow cancer cells to change behavior, invade surrounding tissue, and become resistant to treatment.
The third protects cancer cells during stress by helping them survive oxidative damage, metabolic challenges, and attacks from the immune system.
According to the study, melatonin influences all three systems simultaneously.
Instead of blocking one molecular target, it appears to change the overall physical landscape inside the cell, making it increasingly difficult for cancer’s survival machinery to remain functional.
A Universal Regulator?
The authors describe melatonin as a potential “sovereign singularity,” meaning a master regulator capable of coordinating multiple biological systems at once.
They write that melatonin “systematically alters the cellular environment to render the oncogenic program biophysically unviable.”
Rather than chasing one mutation after another, this framework suggests that changing the physical conditions inside cells may undermine many different cancer pathways simultaneously.
That idea could help explain why previous studies have reported melatonin influencing such a wide range of cancer related processes, including apoptosis, angiogenesis, metastasis, immune regulation, metabolic reprogramming, epigenetic modification, cell cycle regulation, and improved sensitivity to therapy.
Instead of representing unrelated effects, these actions may all arise from one common underlying mechanism.
Why Clinical Results Have Been Mixed
The paper also addresses an important question.
If melatonin has shown so much promise in laboratory research, why have human clinical studies produced inconsistent results?
The researchers argue that most clinical trials have focused on measuring protein or gene levels without considering the physical organization of those molecules inside cells.
Traditional laboratory measurements can determine how much of a protein exists but cannot reveal whether it has been trapped inside one of these protective condensates.
According to the authors, this limitation may have caused researchers to overlook many of melatonin’s most important biological effects.
The investigators emphasize that their work is a proof of concept rather than definitive clinical evidence.
They acknowledge that much of their framework remains theoretical and that future studies will need advanced techniques capable of directly observing these biomolecular condensates in living cells.
Nevertheless, their findings offer a compelling new model that ties together decades of melatonin research into one unified explanation.
If validated through future laboratory and clinical studies, melatonin could represent something very different from a conventional cancer drug. Instead of attacking individual mutations one at a time, it may reshape the entire cellular environment that tumors need to survive.
That possibility could open an entirely new chapter in cancer research, one focused not simply on targeting genes, but on altering the fundamental physical landscape that allows cancer to thrive.